In another study (Palmqvist et al, 2020), plasma NfL had an AUC of 0.51 for separating participants with a high likelihood of AD (tangles in neocortex and moderate‐to‐frequent Aβ plaques) from non‐AD participants (those with none‐to‐sparse Aβ plaques) based on neuropathological assessment (Mirra et al, 1991) and 0.50 for clinical AD dementia vs other neurodegenerative disorders. This evidence concerns the gene NEFL and Alzheimer disease.